Jim Cramer gave a dose of wisdom on a biotech company that is taking on the hemophilia space.
According to a filing from the U.S. Patent and Trademark Office, Forward Pharma has been interfering with Biogen.
Shares of Acorda were hit today after a District Court invalidated four patents for Ampyra, which represents 95 percent of the company's revenue. CNBC's Meg Tirrell reports.
CNBC's Meg Tirrell reports on the latest market action in the bio-tech sector.
The track record in drug development for Alzheimer's disease has been terrible: a success rate of less than 1 percent.
Jim Cramer identified one company with strong fundamentals that’s got the extra kicker of being an attractive takeover.
CNBC's Meg Tirrell reports on the victory for Biogen in its patent case over its Multiple Sclerosis drug.
Traders will likely watch international headlines Friday after the major events of the week have left stocks in a holding pattern.
U.S. stocks closed mostly lower Thursday as modest gains in financial stocks failed to offset declines in health care and utilities stocks.
Biogen shares are fully valued following the spinoff of its hemophilia business, Morgan Stanley argues.
Promising new research suggests that marijuana could be used to treat Alzheimer's, but there's a major roadblock: the federal government.
South Korea's Samsung Bioepis has won a high-stakes court case against U.S. drug firm AbbVie.
The hire signals Carl Icahn may be back, at a time when biotech valuations are 25 percent off their 2015 highs.
CNBC's Meg Tirrell speaks with John Cox, Bioverativ CEO, about the company's spinoff from Biogen, its new innovations in treating hemophilia.
Citi Research says shares of Biogen could rally 15 percent in the next 12 months on the launch of Spinraza.
U.S. stock index futures pointed to a mixed open after the Dow closed above 20,000 points for the first time in the previous session.
Some of the names on the move ahead of the open.
The Dow burst through 20,000 after just a two-month, 1000-point ride, and strategists say stocks could continue to move up for now, as retail investors are lured in.
Here's why the congressman's Cabinet nomination has raised flags for ethics experts, Vox reports.
Morgan Stanley on Friday told clients of a group of stocks that could rally on earnings.